醋甲唑胺治疗2型糖尿病的临床疗效及安全性观察

Clinical Observate the Efficacy and Safety of Oral Methazolamide in Patients with Type 2 Diabetes

目的:评价青光眼治疗药物醋甲唑胺用于2型糖尿病治疗的有效性及安全性。方法:选择我院2型糖尿病初诊患者64例,随机分为两组,其中醋甲唑胺治疗组32例,对照药物二甲双胍32例。观察并比较两组患者治疗前后血糖及糖化血红蛋白水平变化,以及肝肾功能、血尿常规等安全性指标。结果:与治疗前比较,两组患者治疗后糖化血红蛋白水平均下降,差异具有统计学意义(P<0.05);但治疗后两组间糖化血红蛋白水平比较,差异无统计学意义(P>0.05);两组治疗前后肝功肾功等生化指标之间比较,差异无统计学意义(P>0.05);两组用药安全性比较,差异无统计学意义(P>0.05)。结论:醋甲唑胺与二甲双胍具有相似的降血糖疗效,可作为新的治疗糖尿病的二线药物选择性使用。

Objective： To analyze the clinical efficacy and safety of oral methazolamide on the treatment of type 2 diabetes.Methods： 64 cases with type 2 diabetics who were treated without the insulin in our hospital were selected and divided into the methazolamide group and the metformin group with 32 cases in each group. Then the levels of blood glucose, serum insulin and glycosylated hemoglobin and the liver and renal functions were observed and compared between the two groups before and after the treatment. Results： Compared with the metformin group, there was no statistically significant about the levels of glycosylated hemoglobin in the methazolamide group（P〉0.05）; There was statistically significant difference within each group before and after the treatment（P〈0.05）. There was no statistically significant difference about the renal function and the clinical safety between the two groups before and after the treatment（P〉0.05）. Conclusion： The clinical effects of methazolamide and metformin were similar to control the glycosylated hemoglobin, which could be used as a new option to treat type 2 diabetes.